D. Boral Capital Maintains Co-Diagnostics (CODX) Buy Recommendation
Fintel reports that on October 16, 2025, D. Boral Capital maintained coverage of Co-Diagnostics (NasdaqCM:CODX) with a Buy recommendation.
Analyst Price Forecast Suggests 482.86% Upside
As of September 30, 2025, the average one-year price target for Co-Diagnostics is $2.04/share. The forecasts range from a low of $1.01 to a high of $3.15. The average price target represents an increase of 482.86% from its latest reported closing price of $0.35 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Co-Diagnostics is 2MM, an increase of 52.44%. The projected annual non-GAAP EPS is 0.38.
What is the Fund Sentiment?
There are 45 funds or institutions reporting positions in Co-Diagnostics. This is an decrease of 5 owner(s) or 10.00% in the last quarter. Average portfolio weight of all funds dedicated to CODX is 0.00%, an increase of 69.19%. Total shares owned by institutions decreased in the last three months by 16.69% to 5,162K shares. 
The put/call ratio of CODX is 0.03, indicating a bullish outlook.
What are Other Shareholders Doing?
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,276K shares representing 2.65% ownership of the company. No change in the last quarter.
Private Advisory Group holds 1,182K shares representing 2.45% ownership of the company. No change in the last quarter.
Renaissance Technologies holds 561K shares representing 1.17% ownership of the company. In its prior filing, the firm reported owning 550K shares , representing an increase of 1.91%. The firm decreased its portfolio allocation in CODX by 18.90% over the last quarter.
VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 445K shares representing 0.92% ownership of the company. No change in the last quarter.
Geode Capital Management holds 320K shares representing 0.66% ownership of the company. In its prior filing, the firm reported owning 342K shares , representing a decrease of 6.93%. The firm decreased its portfolio allocation in CODX by 24.54% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.